immunotherapy / Fenton Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱

Features:

Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers

PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class	Example Agents	Primary Target	Core Mechanism	Interaction Considerations	Net Effect
PD-1 inhibitors	Nivolumab, Pembrolizumab	PD-1 receptor on T cells	Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity	High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk	↑ Anti-tumor immune activation
PD-L1 inhibitors	Atezolizumab, Durvalumab	PD-L1 on tumor/immune cells	Prevents PD-L1 from engaging PD-1 → enhances T-cell response	Similar immune-related adverse event (irAE) profile as PD-1 inhibitors	↑ Immune activation
CTLA-4 inhibitors	Ipilimumab	CTLA-4 checkpoint	Enhances early T-cell priming in lymph nodes	Higher autoimmune toxicity risk vs PD-1 class	↑ T-cell priming
CAR-T therapy	CD19 CAR-T products	Tumor antigen (e.g., CD19)	Genetically engineered T cells directly target tumor cells	Risk of cytokine release syndrome (CRS) and neurotoxicity	Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint)	Trastuzumab, Rituximab	Specific tumor antigens	Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade	Combination with chemo common; immune activation depends on Fc engagement	Targeted immune-mediated killing
Cytokine therapy	IL-2, IFN-α	Immune activation pathways	Stimulates T-cell and NK cell proliferation	High systemic toxicity; rarely used now vs checkpoint inhibitors	Broad immune stimulation
Cancer vaccines	mRNA or peptide-based	Tumor antigens	Induces tumor-specific immune memory	Often combined with checkpoint blockade	Adaptive immune priming
Bispecific T-cell engagers	Blinatumomab	CD3 + tumor antigen	Bridges T cells directly to tumor cells	CRS risk; continuous infusion in some protocols	Direct T-cell redirection

Fenton, Fenton Reaction: Click to Expand ⟱

Source:

Type:

The Fenton reaction is a chemical reaction that involves the catalytic decomposition of hydrogen peroxide (H2O2) by iron ions (Fe2+ or Fe3+). This reaction produces highly reactive oxygen species (ROS), including hydroxyl radicals (·OH) and superoxide anions (O2·-).
Cancer Progression:
Increased oxidative stress from the Fenton reaction can promote cancer cell proliferation, survival, and metastasis. ROS can activate various signaling pathways that support tumor growth and resistance to apoptosis.
Therapeutic Target:
The Fenton reaction has been explored as a potential therapeutic target. Strategies to manipulate iron levels or enhance the production of ROS in cancer cells are being investigated to selectively induce cell death in tumors.

Formula
Fe2+ + H2O2 → Fe3+ + HO• + OH−
Fe3+ + H2O2 → Fe2+ + HOO• + H+
2 H2O2 → HO• + HOO• + H2O net reaction

– The dysregulation of iron metabolism in certain cancers might serve as a biomarker for targeted treatments that employ Fenton reaction-based strategies.
– Researchers are investigating strategies that harness or amplify the Fenton reaction to selectively kill cancer cells.
- With more available iron, the Fenton reaction can be enhanced, resulting in increased production of hydroxyl radicals. Which can lead to cancer cell death.

See the ROS target for more information

Scientific Papers found: Click to Expand⟱

582-

MF,

immuno,

VitC,

Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy

in-vitro,

Pca,

TRAMP-C1

As shown in Fig. 1a, once AA is released under the MF, ferric ions in IONCs are reduced by AA increasing ferrous ions, which are a stronger inducer for <span class="wphighlight">Fenton</span> reaction compared with ferric ions

in-vivo,

NA,

TRAMP-C1 tumor-bearing mice

Fenton↑, Ferroptosis↑, ROS↑, TumCG↓, Iron↑, GPx4↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Fenton↑, 1, Ferroptosis↑, 1, GPx4↓, 1, Iron↑, 1, ROS↑, 1,

Cell Death ⓘ

Ferroptosis↑, 1,

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,
Total Targets: 7

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Fenton, Fenton Reaction

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells